Drug Database
SU

sulpiride (Lisopiride / Dogmatil / Dogmatil 50)

✓ Approved

Sanofi S.A · DRD2 · 小分子

什么是 sulpiride?

sulpiride 是一种小分子,由Sanofi S.A研发。该药已获批,用于治疗相关适应症。

药物档案

商品名Lisopiride, Dogmatil, Dogmatil 50
公司Sanofi S.A
药物类别小分子
分子靶点DRD2
状态Approved

作用机制

分子靶点

sulpiride 作用于 1 个分子靶点:

DRD2dopamine receptor D2 (D2DR, D2R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

sulpiride 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersMetabolic disorder✓ Approved

相关研究文献

PubMedPharmacological research2026-10-28

Striatofugal balance and beneficial effects of facilitating nucleus accumbens mGlu4 receptor activity in the Fmr1-/- mouse model of Fragile X Syndrome.

Fonteneau Mathieu M, Terrier Claire C, Bolot Florian F, Pantouli Fani F et al.

Fragile X Syndrome (FXS) is the leading monogenic cause of autism spectrum disorder (ASD). To date, no approved pharmacological treatment alleviates social impairments in patients with FXS. Since D1 and D2 dopamine receptor-expressing striatal projection neurons (SPNs) were shown to regulate ASD-sensitive behaviors, we explored whether the balance of activity between D1- and D2-SPNs would be biased in the Fmr1-/- mouse model of FXS. We evaluated striatal function in Fmr1-/- and Fmr1+/+ mice under pharmacological challenge and performed RNAscope® in situ hybridization following social interaction to assess the activity of SPNs in the nucleus accumbens (NAc) and dorsal striatum. We evidenced a decrease in D1-SPN activity, biasing the D1/D2-SPN balance. We then evaluated the effects of compounds developed to repress D2-SPN activity on behavioral impairments in Fmr1-/- mice. Systemically facilitating mGlu4 or blocking A2a receptor activity relieved behavioral deficits in this model. Moreover, social interaction in Fmr1-/- mice was fully rescued by photopharmacological activation of mGlu4 in the ventral pallidum, to which both NAc D1- and D2-SPNs project, and mGlu4 receptors in the NAc likely contributed to restoring social deficits after systemic mGlu4 facilitation. Together, these results are consistent with our working hypotheses of both biased striatal D1/D2-SPN balance in social deficit and contribution of mGlu4 receptors expressed by NAc SPNs in modulating social behavior. In conclusion, pharmacological compounds able to regulate SPN activity demonstrate a promising therapeutic potential to relieve ASD-like deficits in FXS. PHARMACOLOGICAL COMPOUNDS: ADX88178 (CAS 1235318-89-4); haloperidol hydrochloride (CAS 1511-16-6); istradefylline (CAS 155270-99-8); LSP4-2022 (CAS 1413405-33-0); morphine hydrochloride (CAS 6055-06-7); quinpirole hydrochloride (CAS 85798-08-9); SCH-23390 hydrochloride (CAS 125941-87-9); SKF-81297 hydrobromide (CAS 67287-39-2); sulpiride (CAS 15676-16-1); VU0155041 sodium (CAS 1259372-69-4); optogluram (CAS 1627840-48-5).

PMID 42951119
阅读全文 →
PubMedBehavioural pharmacology2026-10-25

Reciprocal blockade of the opioid and D2-like dopamine receptors in the nucleus accumbens modulates the pain-related behaviors in an animal model of inflammatory pain.

Khodabakhsh Helia H, Ghalandari-Shamami Mohadeseh M, Barikrow Nooshin N, Yekta Batool Ghorbani BG et al.

Studies showed that dopamine and opioid systems in the brain have essential role in the modulation of pain perception. The evidence indicated that in the nucleus accumbens (NAc), both dopamine type 2 (D2) receptors and opioid receptors are highly expressed. However, the interaction of these systems in NAc was not investigated in the modulation of inflammatory pain. One hundred twenty-six adult male Wistar rats received unilateral microinjections of different doses of morphine (2.5, 5, 10, and 25 mmol/0.5 μl) and quinpirole (8, 16, and 32 mmol/0.5 μl) to assess their effects as opioid and D2-like receptor agonists in the NAc. In the next step, the rats were administered varying doses of sulpiride (3, 6, 12, and 24 mmol/0.5 μl), a D2-like receptor antagonist, before an effective dose of quinpirole (32 mmol/0.5 μl). They also received naloxone (1.5, 5, and 15 mmol/0.5 μl) before the same effective dose of quinpirole (32 mmol/0.5 μl). The formalin test was employed to evaluate their inflammatory pain thresholds. Results indicated that intra-accumbal administration of morphine- and quinpirole-induced antinociceptive responses. However, sulpiride significantly diminished these responses. Naloxone also reduced the quinpirole's antinociceptive effects. Interestingly, sulpiride was less effective in reversing the analgesic effects of morphine ( η2  = 0.17 in the first phase and η2  = 0.37 in the late phase) than naloxone in reversing the quinpirole's analgesic effects ( η2  = 0.4 in the first phase and η2  = 0.53 in the late phase). These findings suggest an interaction between the opioidergic and dopaminergic systems in pain relief.

PMID 42924872
阅读全文 →
PubMedNeuroscience research2026-10-04

Centrally administered SGLT2 inhibitor improves gut barrier function through the brain orexin, AMPK, dopamine D2 signaling and the vagal pathway in rats.

Funayama Takuya T, Nozu Tsukasa T, Ishioh Masatomo M, Sumi Chihiro C et al.

Leaky gut, defined as increased intestinal permeability, has been associated with many diseases. Recent studies suggest the brain is involved in maintaining gut barrier function. Since tofogliflozin, a sodium/glucose cotransporter 2 (SGLT2) inhibitor acts centrally to increase food intake, and feeding and gut functions are deeply associated, this study aimed to clarify the hypothesis that gut barrier function is influenced by centrally administered SGLT2 inhibitors in rats using Evans blue method. Intracisternal SGLT2 inhibitor blocked colonic hyperpermeability in response to lipopolysaccharide dose-dependently (15 μg-). The blockade was cancelled by atropine, vagotomy, intracisternal orexin receptor antagonist, intracisternal compound C, an adenosine monophosphate-activated protein kinase (AMPK) inhibitor, or subcutaneously injected sulpiride, a dopamine D2 receptor antagonist. Subcutaneous SGLT2 inhibitor at much higher doses of 5 mg or more could improve colonic hyperpermeability, and the improvement was also blocked by atropine or intracisternal orexin receptor antagonist or compound C. These results indicate SGLT2 inhibitor administered centrally or peripherally reduces colonic hyperpermeability through the vagal pathway although we could not exclude the possibility that peripherally administered SGLT2 inhibitor might act first in periphery. Brain orexin, AMPK and dopamine D2 signaling are involved in this process. SGLT2 inhibitors may be useful to treat leaky gut-related diseases.

PMID 42829074
阅读全文 →
PubMedMethods and protocols2026-09-23

Comparison of the Utility of Amplitude-Spectral and Coherence Features of Psychotropic Drugs' Action on ECoG Signal for Pharmaco-EEG Based Drug Screening in Rats.

Sysoev Yuriy I YI, Kurmazov Nikita S NS, Shitc Darya D DD, Okovityi Sergey V SV

A naive Bayesian classifier (NBC) combined with principal component analysis (PCA) effectively differentiates the dose-dependent effects of certain groups of psychoactive drugs based on their impact on the amplitude-spectral characteristics of electrocorticograms (ECoG) in rats. This approach has been shown to be useful for pharmacological screening of agents with unknown or poorly understood activity. Despite previously obtained optimistic results, classification determination for some drugs was inaccurate, necessitating the search for possible ways to improve the predictive effectiveness of the proposed algorithm. One possible approach would be to use as input quantitative data not only the impact of the psychoactive drugs studied on the amplitude-spectral characteristics of ECoG but also connectivity changes, including the average coherence power of different pairs of leads. The aim of this study was to compare the accuracy of NBC in classifying the pharmacological mechanism of action of agents with well-known mechanisms (test set) using pharmaco-EEG data on changes in the amplitude-spectral characteristics of ECoG, coherence, and the combined use of two data sets. Materials and methods. Experiments were performed on Wistar rats with chronically implanted ECoG electrodes. The training set, relative to which the effects of the pharmacological agents from the test set were classified, were the matrices of effects of 12 pharmacological agents: the NMDA antagonist dizocilpine, the D2/D3 antagonists haloperidol and sulpiride, the M-anticholinergic tropicamide, the H1/5HT2A receptor blocker hydroxyzine, the acetylcholinesterase inhibitor galantamine, the alpha-2 adrenergic agonist dexmedetomidine, the alpha-2 adrenergic antagonist atipamezole, the adenosine receptor blocker caffeine and the GABA-mimetics aminophenylbutyric acid (phenibut), bromdihydrochlorophenylbenzodiazepine (phenazepam) and 5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione. The test set included various drugs with tropism for the targets of the training set drugs: dopamine receptor antagonists chlorpromazine, droperidol, tiapride and raclopride, H1-histamine blockers diphenhydramine and promethazine, 5-HT2-receptor blockers ritanserin and glemenserin, acetylcholinesterase inhibitor ipidacrine, alpha2-adrenergic receptor antagonist yohimbine, alpha2-adrenergic agonists medetomidine and xylazine, GABA-mimetics 5-ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione and chloral hydrate. The analysis of the ECoG signal included the calculation of 132 amplitude-spectral characteristics and 75 coherence indicators, which, using the PCA, led to new integrative indicators used for further classification of the NBC. Results and discussion. For each drug in the test set, the median similarity probability with a particular group from the training set was calculated, which was used to assess the classification quality. It was found that, when using the amplitude-spectral characteristics of ECoG, the proposed methodological approach allows for the identification of the ECoG effects of several groups of psychoactive drugs, including D2/D3-dopamine, M-cholinergic, H1-histamine, and 5-HT2-serotonin receptor blockers, AChE inhibitors, GABA-mimetics, and alpha-2-adrenergic receptor agonists and antagonists. This approach enabled the correct classification of 18 of 24 groups in the test set. When using changes in coherence indices as the initial data, the classification accuracy also amounted to 18 of 24 groups. When combining the two data sets, the number of correctly identified NBC groups was 20 of 24 groups. When comparing the classification during training (confusion matrix), it was found that coherence data or adding coherence data to the data based on changes in amplitude-spectral characteristics leads to a statistically significant (p < 0.01 in both cases) increase in accuracy. Conclusions. The obtained data demonstrated high accuracy in classifying the pharmacological activity of the test sample drugs using any of the three compared approaches. Despite the lack of statistically significant differences between them, classification based on the combined dataset demonstrated a higher number of "correct" similarities. This allows us to recommend the approach based on combined data of drug effects on amplitude-spectral characteristics and coherence as the most promising for further studies using pharmaco-EEG screening.

PMID 42776676
阅读全文 →
PubMedFrontiers in pharmacology2026-09-22

Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study.

Shao Yong Y, Lu Zhe Z, Zhang Yuyanan Y, Wang Xueping X

Hyperprolactinemia (HPRL) is a common adverse reaction induced by antipsychotic therapy in patients with schizophrenia, which greatly undermines medication adherence and impairs physiological functions of multiple body systems. In this real-world study, we analyzed retrospective prolactin testing data to compare the incidence of HPRL between schizophrenia patients and patients with other psychiatric disorders, so as to identify clinical high-risk factors. Meanwhile, hormones including thyroid-stimulating hormone (TSH), free tetraiodothyronine (FT4), free triiodothyronine (FT3), tetraiodothyronine (T4), Triiodothyronine (T3), and estradiol that closely correlated with prolactin metabolism were also included in the analysis. The results indicated that female patients with schizophrenia had the highest risk of HPRL (19.31%, n = 2009), and women during the prime reproductive (25-40 years) showed the highest average prolactin concentration (1,389.22 ± 50.138 mIU/L, n = 966). Distinct antipsychotics usage rates were observed among different clinical subgroups. Risperidone, paliperidone and sulpiride showed an increasing trend with elevated PRL levels, whereas quetiapine and aripiprazole were more frequently prescribed in the low-risk HPRL group. Antipsychotics showed divergent dopamine D2/D3 and 5-HT2A receptor-binding affinities (Ki values), and we constructed a weighted multi-receptor affinity index that demonstrated a strong linear correlation with the PRL risk score (R2 = 0.878). Additionally, the average incidence of extrapyramidal symptoms (EPS) increased with rising PRL levels (P = 2.24E-10). Further analysis of EPS risk revealed distinct safety profiles across antipsychotics, with aripiprazole-characterized by low HPRL liability-demonstrating a higher EPS risk. The severe HPRL group presented a tendency of decreased thyroid function (TSH, P = 0.0027; FT4, P = 0.000031; FT3, P = 0.0076; T4, P = 0.0025) and a significant reduction in estradiol levels (P = 0.000049). Based on homogeneous clinical real-world data, this study comprehensively evaluated multiple antipsychotic medications simultaneously. It provides empirical clinical evidence for individualized medication strategies in patients with comorbid HPRL and EPS, and offers real-world evidence for the clinical early risk recognition, and long-term medication decision-making among patients with multiple adverse reactions concurrently.

PMID 42769084
阅读全文 →
PubMedThe Journal of neuroscience : the official journal of the Society for Neuroscience2026-09-15

Visualizing Synaptic Disruptions in the Release and Regulation of Dopamine Hotspots in Huntington's Disease.

Yang Sarah J SJ, Komatsu Natsumi N, Butler Brendan B, Del Bonis-O'Donnell Jackson Travis JT et al.

Dopamine neuromodulation is a critical process that facilitates learning, motivation, and motor control. Disruption of these processes has been implicated in several neurodegenerative disorders including Huntington's disease (HD). While dopaminergic signaling is a therapeutic target for treating physical and psychiatric HD symptoms, the mechanism by which dopaminergic dysfunction occurs during HD is unknown. New tools for the visualization of dopamine dynamics at the spatiotemporal resolution of neuromodulator release (milliseconds) and dopaminergic boutons (micrometers) provide a richer understanding of how dopamine signaling is disrupted in HD. Here we employ near-infrared catecholamine nanosensors (nIRCats) to image dopamine release within the striatum of R6/2 HD model mice of either sex. We find that dorsal striatal dopamine release decreases with progressive degeneration and that these deficits are primarily driven by a decrease in the number of nIRCat-imaged dopamine release sites, termed dopamine hotspots, combined with their decreased dopamine release fidelity. Using nIRCat's high spatial resolution, we track individual dopamine hotspots over repeated stimulations and pharmacological applications to measure dopamine release fidelity from individual sites. Compellingly, we found that D2-receptor (D2R) antagonist sulpiride drives increased fidelity of dopamine hotspot activity in the wild-type striatum but not in the late-disease HD striatum, suggesting that D2R regulation of dopamine release is compromised in late HD. These findings, enabled by nIRCats, provide more detailed insights into how dopamine release is disrupted and dysregulated during HD.

PMID 42744615
阅读全文 →

注册免费账户还可查看另外 5108 篇文献

免费注册查看全部文献 →

了解更多sulpiride